Synpromics, Avalanche Announce Deal
News Dec 18, 2015
Synpromics will develop synthetic promoters for use with Avalanche’s Ocular BioFactoryTM platform technology. Synpromics' technology creates highly specific promoters that control gene expression. These promoters are designed to be specific to the target cell type and aim to enable a precise level of control of gene expression.
Dr David Venables, CEO of Synpromics, commented, “This is our fourth collaboration in the field of gene therapy and further validation of the wide applicability of our platform. Avalanche Biotechnologies is developing next generation gene therapy technologies to treat eye diseases and we believe that Synpromics’ technology has the potential to support the development of these next generation therapeutics.”
Minoryx Therapeutics spins off SEE-Tx platform into new company, Gain TherapeuticsNews
The new Swiss company will operate in Lugano and Barcelona under the scientific management of Minoryx co-founder Dr Xavier Barril.READ MORE
Evolution Threatens Efficient Bioproduction Scale-UpNews
The transition towards sustainable biobased chemical production is important for green growth, but productivity and yield of engineered cells frequently decrease in large industry-scale fermentation. According to a new study, the role of evolution has been underestimated in limiting bioprocesses.
Comments | 0 ADD COMMENT
World Advanced Therapies & Regenerative Medicine Congress
May 16 - May 18, 2018